Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress

Hikma Pharmaceuticals outlined a more centralized R&D strategy at the first event in its R&D Spotlight series. The company highlighted investments in respiratory, nasal, semi-solid and liquid products, along with its approach to developing higher-complexity medicines; no financial figures or market reaction were reported.